Cargando…

Specific inhibition of one DNMT1-including complex influences tumor initiation and progression

BACKGROUND: Reactivation of silenced tumor suppressor genes by DNMT inhibitors has provided an alternative approach to cancer therapy. However, DNMT inhibitors have also been shown to induce or enhance tumorigenesis via DNA hypomethylation-induced oncogene activation and chromosomal instability. To...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheray, Mathilde, Pacaud, Romain, Nadaradjane, Arulraj, Vallette, François M, Cartron, Pierre-François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727981/
https://www.ncbi.nlm.nih.gov/pubmed/23809695
http://dx.doi.org/10.1186/1868-7083-5-9
_version_ 1782278785808203776
author Cheray, Mathilde
Pacaud, Romain
Nadaradjane, Arulraj
Vallette, François M
Cartron, Pierre-François
author_facet Cheray, Mathilde
Pacaud, Romain
Nadaradjane, Arulraj
Vallette, François M
Cartron, Pierre-François
author_sort Cheray, Mathilde
collection PubMed
description BACKGROUND: Reactivation of silenced tumor suppressor genes by DNMT inhibitors has provided an alternative approach to cancer therapy. However, DNMT inhibitors have also been shown to induce or enhance tumorigenesis via DNA hypomethylation-induced oncogene activation and chromosomal instability. To develop more specific DNMT inhibitors for efficient cancer therapy, we compared the effects of peptides designed to specifically disrupt the interaction of DNMT1 with different proteins. FINDINGS: Our data indicated that the use of an unspecific DNMT inhibitor (5aza-2deoxycytidine), a DNMT1 inhibitor (procainamide) or peptides disrupting the DNMT1/PCNA, DNMT1/EZH2, DNMT1/HDAC1, DNMT1/DNMT3b and DNMT1/HP1 interactions promoted or enhanced in vivo tumorigenesis in a mouse glioma model. In contrast, a peptide disrupting the DNMT1/DMAP1 interaction, which per se did not affect tumor growth, sensitized cancer cells to chemotherapy/irradiation-induced cell death. Finally, our data indicated that the peptide disrupting the DNMT1/DMAP1 interaction increased the efficiency of temozolomide treatment. CONCLUSION: Our data suggest that the DNMT1/DMAP1 interaction could be an effective anti-cancer target and opens a new avenue for the development of new strategies to design DNMT inhibitors.
format Online
Article
Text
id pubmed-3727981
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37279812013-07-31 Specific inhibition of one DNMT1-including complex influences tumor initiation and progression Cheray, Mathilde Pacaud, Romain Nadaradjane, Arulraj Vallette, François M Cartron, Pierre-François Clin Epigenetics Short Report BACKGROUND: Reactivation of silenced tumor suppressor genes by DNMT inhibitors has provided an alternative approach to cancer therapy. However, DNMT inhibitors have also been shown to induce or enhance tumorigenesis via DNA hypomethylation-induced oncogene activation and chromosomal instability. To develop more specific DNMT inhibitors for efficient cancer therapy, we compared the effects of peptides designed to specifically disrupt the interaction of DNMT1 with different proteins. FINDINGS: Our data indicated that the use of an unspecific DNMT inhibitor (5aza-2deoxycytidine), a DNMT1 inhibitor (procainamide) or peptides disrupting the DNMT1/PCNA, DNMT1/EZH2, DNMT1/HDAC1, DNMT1/DNMT3b and DNMT1/HP1 interactions promoted or enhanced in vivo tumorigenesis in a mouse glioma model. In contrast, a peptide disrupting the DNMT1/DMAP1 interaction, which per se did not affect tumor growth, sensitized cancer cells to chemotherapy/irradiation-induced cell death. Finally, our data indicated that the peptide disrupting the DNMT1/DMAP1 interaction increased the efficiency of temozolomide treatment. CONCLUSION: Our data suggest that the DNMT1/DMAP1 interaction could be an effective anti-cancer target and opens a new avenue for the development of new strategies to design DNMT inhibitors. BioMed Central 2013-06-28 /pmc/articles/PMC3727981/ /pubmed/23809695 http://dx.doi.org/10.1186/1868-7083-5-9 Text en Copyright © 2013 Cheray et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Cheray, Mathilde
Pacaud, Romain
Nadaradjane, Arulraj
Vallette, François M
Cartron, Pierre-François
Specific inhibition of one DNMT1-including complex influences tumor initiation and progression
title Specific inhibition of one DNMT1-including complex influences tumor initiation and progression
title_full Specific inhibition of one DNMT1-including complex influences tumor initiation and progression
title_fullStr Specific inhibition of one DNMT1-including complex influences tumor initiation and progression
title_full_unstemmed Specific inhibition of one DNMT1-including complex influences tumor initiation and progression
title_short Specific inhibition of one DNMT1-including complex influences tumor initiation and progression
title_sort specific inhibition of one dnmt1-including complex influences tumor initiation and progression
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727981/
https://www.ncbi.nlm.nih.gov/pubmed/23809695
http://dx.doi.org/10.1186/1868-7083-5-9
work_keys_str_mv AT cheraymathilde specificinhibitionofonednmt1includingcomplexinfluencestumorinitiationandprogression
AT pacaudromain specificinhibitionofonednmt1includingcomplexinfluencestumorinitiationandprogression
AT nadaradjanearulraj specificinhibitionofonednmt1includingcomplexinfluencestumorinitiationandprogression
AT vallettefrancoism specificinhibitionofonednmt1includingcomplexinfluencestumorinitiationandprogression
AT cartronpierrefrancois specificinhibitionofonednmt1includingcomplexinfluencestumorinitiationandprogression